β-Glucan Composition for Hormone-Dependent Dermatitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hormone-dependent dermatitis, caused by long-term use of topical glucocorticoids, are ineffective, prolonged, and prone to recurrence, leading to physical and psychological harm.
Innovation Solution
The use of β-glucan, particularly β-1,3-glucan with a triple helix structure and high molecular weight, is formulated into compositions to prevent and treat hormone-dependent dermatitis by enhancing skin immunity and accelerating healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticoids are used long-term to treat dermatitis, then anti-inflammatory effect is improved, but hormone-dependent dermatitis occurs and becomes difficult to cure
Solution Approach 1:
The patent introduces β-glucan as an intermediary substance that mediates between the need for anti-inflammatory treatment and the harmful effects of long-term glucocorticoid use. β-glucan acts as a biological response modifier that enhances the body's own immune defense mechanisms, providing anti-inflammatory effects without the harmful side effects of hormones. It serves as a bridge that allows continued treatment while avoiding hormone dependence.
Solution Approach 2:
The patent changes the fundamental parameter of treatment approach from exogenous hormone supplementation to endogenous immune system modulation. By using β-glucan to stimulate the body's own immune cells (macrophages, natural killer cells), the treatment parameter shifts from chemical anti-inflammatory agents to biological immune enhancement, fundamentally changing how anti-inflammatory effects are achieved.
2Ease of manufacture
If conventional treatment methods are used for hormone-dependent dermatitis, then treatment is provided, but treatment period is prolonged and recurrence is frequent
Solution Approach 1:
The patent applies preliminary action by using β-glucan to restore and strengthen skin immune function before hormone-dependent dermatitis fully develops or recurs. By continuously modulating the immune system with β-glucan, the skin maintains better defense capability, preventing the condition from worsening and reducing the likelihood of recurrence, thereby shortening overall treatment duration.
Solution Approach 2:
The patent incorporates feedback mechanisms where β-glucan continuously interacts with and modulates the immune system's response. This creates a dynamic feedback loop that adapts to the skin's changing immune status, providing ongoing adjustment and optimization of the immune response, which helps prevent recurrence and reduces treatment time.
3Object-affected harmful factors
If glucocorticoids are used to treat dermatitis, then inflammatory symptoms are suppressed, but skin defense function is weakened and recurrence occurs
Solution Approach 1:
The patent applies inversion by reversing the conventional approach: instead of suppressing immune function to reduce inflammation (as glucocorticoids do), β-glucan enhances immune function to naturally control inflammation. This inverted approach achieves anti-inflammatory effects through immune enhancement rather than immune suppression, thereby maintaining skin defense function while treating inflammatory symptoms.
Data Source
AI summary
A composition contains β-glucan and is used for preventing and/or treating hormone-dependent dermatitis, skin mucositis or other skin inflammatory diseases.